Tenaya AAV-Reprogramming

Tenaya AAV-Reprogramming is an investigational gene therapy developed by Tenaya Therapeutics for cardiac regeneration following myocardial infarction. It utilizes a novel adeno-associated virus (AAV) vector to deliver a proprietary combination of three genes and regulatory elements directly into the heart. The therapy is designed to convert resident cardiac fibroblasts (CFs) into new cardiomyocytes (CMs), thereby regenerating functional heart tissue after ischemic injury. The construct incorporates regulatory elements that enhance expression in CFs while detargeting preexisting and newly formed CMs. Preclinical studies in rodent models have demonstrated dose-dependent and durable improvements in cardiac function post-infarction, with evidence supporting new CM formation as the mechanism of action[1][3][6]. This approach represents a first-in-class attempt at direct in vivo cellular reprogramming for chronic heart failure due to scar formation.

Other names

Tenaya cardiac reprogramming AAVTenaya cellular reprogramming product candidate